Key Developments: Diaxonhit (EXHTF.PK)
2.40USD
14 Feb 2012
$0.00 (+0.00%)
$2.40
--
$2.40
$2.40
300
0
$2.40
$2.40
Latest Key Developments (Source: Significant Developments)
Diaxonhit SA Wins Public Tender from the Paris Hospitals (Assistance Publique – Hopitaux de Paris)
Diaxonhit SA announced that it has won through its marketing subsidiary InGen, a tender from the AGEPS, the Paris Hospitals' (Assistance Publique - Hopitaux de Paris, AP-HP) central purchasing agency. It involves the supply of tests necessary to perform histocompatibility studies in the context of transplantation activities. The tender covers the next two years and represents potential revenues of up to EUR 5.5 million per year. Full Article
Diaxonhit SA's InGen Wins National Public Tenders from the French Blood Bank
Diaxonhit SA announced the award to its marketing affiliate, InGen, of four national public tenders from the French Blood Bank (EFS). They involve supplying the EFS with tests necessary to perform Human Leucocyte Antigen (HLA) typing and monitoring in the field of transplantation. These tenders cover the next four years, and represent potential revenues of up to EUR 13.8 million by the end of 2016. Full Article
Exonhit SA Completes Acquisition of InGen BioSciences; Changes Name to InGen BioSciences
Exonhit SA announced that following the completion of the acquisition of InGen BioSciences, it has changed its name to Diaxonhit. The financial terms of the acquisition were not disclosed. Full Article
Exonhit SA Announces EUR 1.7 Million Capital Increase
Exonhit SA announced that it has completed a EUR 1.7 million capital increase. The capital increase took place by means of a private placement in France and outside France, with the exclusion of Canada, Australia and Japan, at a price of EUR 0.75 per share. The Company issued 2,247,666 new shares. Societe Generale Corporate & Investment Banking acted as bookrunner for the issue. Full Article
Exonhit SA Announces EUR 6 Million Capital Increase
Exonhit SA announced a capital increase by private placement in France and outside France worth approximately EUR 6 million. Societe Generale Corporate & Investment Banking is acting as bookrunner for the share issue. The price and number of the shares to be issued will be announced when the process of completing the order book has been completed. The dilution of the Company's share capital which will result from the share issue will not exceed 20% of the 34,491,657 shares currently in circulation. Full Article
Exonhit SA Announces Upcoming Acquisition of InGen BioSciences
Exonhit SA announced that it entered into an agreement to acquire 100% of InGen BioSciences SA from its founders and financial shareholders, IPSA (ex Innoven Partenaires) and funds managed by Amundi Private Equity Funds. Subject to customary precedent conditions, as well as a financing through a private placement, this acquisition is expected to close in December 2012 following approval from Exonhit`s shareholders. The total purchase price of EUR 18 million will be paid in cash for EUR 8 million and the balance in Exonhit stock, to be issued to InGen BioSciences` shareholders. This issuance of new shares will be subject to approval by Exonhit`s shareholders during a shareholders` extraordinary general meeting to be scheduled for December 2012. Full Article
Exonhit SA Announces Completion of EUR 454 Million Capital Increase
ExonHit Therapeutics SA announced that it has raised EUR 454 million following a capital increase reserved to specific investors. The Company issued 360,260 new shares at a unit price of EUR 1.26 per share. Full Article
Exonhit SA Receives Grant from European Union Through Participation in Responsify Consortium
Exonhit SA announced that it is the beneficiary of a EUR 418,000 grant from the European Union through its participation in the RESPONSIFY consortium. RESPONSIFY is a European consortium of 12 partners focusing on personalized medicine in oncology. Its objective is to identify predictive biomarkers of response to two common chemotherapeutic treatments of breast cancer, anti-HER2 (Herceptin) and anti-angiogenic (Avastin) therapies. The goal is to develop CE marked IVD tests that will be approved for current clinical practice. Exonhit brings to the project its proprietary Genome Wide SpliceArray (GWSA) platform, which will be used to analyze patient transcriptomic profiles. The Company will be in charge of filing for IP protection with respect to relevant molecular signatures and associated tests, as well as ensuring CE marking and commercialization of predictive tests identified on its platform. Full Article
ExonHit Therapeutics SA Announces Launch of Observational Study in France
ExonHit Therapeutics SA announced the launch of its observational study in France aimed at evaluating the performance of AclarusDx, a blood-based test intended to aid in the diagnosis of Alzheimer's disease (AD), in patients consulting for the first time with a specialized memory center for AD diagnostic work-up. This real-life study named DIALOG (DIagnostic ALzheimer cOGnitif) is sponsored by ExonHit and has received all regulatory approvals. Full Article
ExonHit Therapeutics SA Extends Strategic Collaboration With Allergan
ExonHit Therapeutics SA announced the extension of its existing drug discovery collaboration with Allergan Sales, LLC. The collaboration was initiated in December 2002, and extended several times. It now is further extended until December 2013. The collaboration will continue to focus on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology. Detailed financial terms were not disclosed. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
